Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis.
Giorgio PiacentiniAlessandro FiocchiGianluigi MarsegliaMichele Miraglia Del GiudiceRenato CutreraRossella BitontiFrancesca FanelliAnnalisa StassaldiGiuliana NicolosiGianluca FurneriPublished in: The World Allergy Organization journal (2024)
The simultaneous testing of multiple biomarkers during baseline patient assessment and disease follow-up is highly recommended. Utilizing cost-effective tests, physicians can estimate the prevalence of severe Type 2 asthma, categorize patients into distinct phenotypes (eosinophilic, allergic, or mixed), and consequently identify and prescribe the most suitable therapeutic interventions. This approach also facilitates the ongoing evaluation and adjustment of the treatment strategies based on individual patient responses.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- chronic obstructive pulmonary disease
- prognostic factors
- peritoneal dialysis
- intensive care unit
- emergency department
- case report
- primary care
- lung function
- physical activity
- risk factors
- patient reported outcomes
- allergic rhinitis
- cystic fibrosis
- early onset
- atopic dermatitis
- chronic rhinosinusitis